These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28903326)

  • 1. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.
    Caliò A; Eble JN; Hes O; Martignoni G; Harari SE; Williamson SR; Brunelli M; Osunkoya AO; Wang L; Comperat E; Lopez-Beltran A; Wang M; Zhang S; Curless KL; Post KM; Chang HY; Luchini C; Baldrige LA; MacLennan GT; Montironi R; Grignon DJ; Cheng L
    Oncotarget; 2017 Aug; 8(33):54096-54105. PubMed ID: 28903326
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular features of metanephric adenoma and their values in differential diagnosis].
    Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF; Navina S; Cressman KL; Pai RK
    Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutations in pediatric metanephric tumors.
    Chami R; Yin M; Marrano P; Teerapakpinyo C; Shuangshoti S; Thorner PS
    Hum Pathol; 2015 Aug; 46(8):1153-61. PubMed ID: 26014474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with
    Suh MS; Choi YD; Lee JB; Lee SC; Won YH; Yun SJ
    Ann Dermatol; 2018 Oct; 30(5):556-561. PubMed ID: 33911478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.
    Wobker SE; Matoso A; Pratilas CA; Mangray S; Zheng G; Lin MT; Debeljak M; Epstein JI; Argani P
    Am J Surg Pathol; 2019 Sep; 43(9):1157-1169. PubMed ID: 31192863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression profiles of BRAF (V600E/VE1) in serrated colon polyps in Turkish population.
    Kokenek-Unal TD; Senel F; Gurcay N; Tasdemir A; Coban I
    Int J Clin Exp Pathol; 2017; 10(8):8868-8874. PubMed ID: 31966754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process.
    Lenci N; Francesco P; Scarciglia E; Fiorentino V; Schino M; Palermo G; Racioppi M; Bassi P; Martini M
    Med Mol Morphol; 2021 Jun; 54(2):187-191. PubMed ID: 33175195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical metanephric adenoma: Shares similar histopathological features and molecular changes of metanephric adenoma and epithelial-predominant Wilms' tumor.
    Yin X; Zhang X; Pan X; Tan J; Zheng L; Zhou Q; Chen N
    Front Oncol; 2022; 12():1020456. PubMed ID: 36313688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring
    Kwon JH; Jeong BK; Yoon YS; Yu CS; Kim J
    J Pathol Transl Med; 2018 May; 52(3):157-163. PubMed ID: 29590746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
    Chan E; Stohr BA; Croom NA; Cho SJ; Garg K; Troxell ML; Higgins JP; Bean GR
    Histopathology; 2020 Jun; 76(7):1084-1090. PubMed ID: 32064677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
    Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
    Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult Wilms Tumor: Genetic Evidence of Origin of a Subset of Cases From Metanephric Adenoma.
    Argani P; Tickoo SK; Matoso A; Pratilas CA; Mehra R; Tretiakova M; Sibony M; Meeker AK; Lin MT; Reuter VE; Epstein JI; Gagan J; Palsgrove DN
    Am J Surg Pathol; 2022 Jul; 46(7):988-999. PubMed ID: 35184066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.